Pleiotropic effects of morphine-6β-glucuronide

Anesthesiology

Volumn 110, Issue 6, 2009, Pages 1209-1210

  Lötsch, Jörn ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR; GLUTAMATE TRANSPORTER; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; MU OPIATE RECEPTOR; DELTA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR; MORPHINE DERIVATIVE; MORPHINE-3-GLUCURONIDE; MORPHINE-6-GLUCURONIDE; NARCOTIC ANALGESIC AGENT;

ALLODYNIA; ANALGESIC ACTIVITY; BLOOD BRAIN BARRIER; COMA; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG GLUCURONIDATION; DRUG HALF LIFE; EDITORIAL; HYPERALGESIA; KIDNEY CLEARANCE; KNOCKOUT MOUSE; MOUSE; NONHUMAN; OPIOID INDUCED EMESIS; PLASMA CLEARANCE; PLEIOTROPY; PRIORITY JOURNAL; RESPIRATION DEPRESSION; SEDATION; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG POTENTIATION; GENETICS; METABOLISM; MOUSE MUTANT; NOTE;

ANALGESICS, OPIOID; ANIMALS; HYPERALGESIA; MICE; MICE, KNOCKOUT; MORPHINE; MORPHINE DERIVATIVES; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU;

EID: 67049098505     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e3181a1075b     Document Type: Editorial

References (27)

1. Huxtable RJ, Schwarz SK: The isolation of morphine: First principles in science and ethics. Mol Interv 2001; 1:189-91
2. van Dorp ELA, Kest B, Kowalczyk WJ, Morariu AM, Waxman AR, Arout CA, Dahan A, Sarton EY: Morphine-6ß-glucuronide rapidly increases pain sensitivity independently of opioid receptor activity in mice and humans. ANESTHESIOIOGY 2009; 110:1356-63
3. Hasselstr̈m J, Säwe J: Morphine pharmacokinetics and metabolism in humans: Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. Clin Pharmacokinet 1993; 24:344-54
4. Pasternak GW, Bodnar RJ, Clark JA, Inturrisi CE: Morphine-6-glucuronide, a potent mu agonist. Life Sci 1987; 41:2845-9
5. Skarke C, DarimontJ, Schmidt H, Geisslinger G, L̈tschJ: Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin Pharmacol Ther 2003; 73:107-21
6. Hanks GW, Hoskin PJ, Aherne GW, Turner P, Poulain P: Explanation for potency of repeated oral doses of morphine? Lancet 1987; 2:723-5
7. Angst MS, Bührer M, Lötsch J: Insidious intoxication after morphine treatment in renal failure: Delayed onset of morphine-6-glucuronide action. ANESTHESIOIOGY 2000; 92:1473-6
8. Hasselström J, Berg U, Lofgren A, Säwe J: Long lasting respiratory depression induced by morphine-6-glucuronide? Br J Clin Pharmacol 1989; 27:515-8
9. Thompson PI, Hucks D, McLoughlin L, Grossman A, Rees L, Slevin M: Comparative opiate receptor affinities of morphine and its active metabolite morphine-6-glucuronide. Br J Cancer 1990; 62:484
10. Rossi GC, Pan YX, Brown GP, Pasternak GW: Antisense mapping the MoR-1 opioid receptor: Evidence for alternative splicing and a novel morphine-6 beta-glucuronide receptor. FEBS Lett 1995; 369:192-6
11. Rossi GC, Standifer KM, Pasternak GW: Differential blockade of morphine and morphine-6 beta-glucuronide analgesia by antisense oligodeoxynucleotides directed against MoR-1 and G-protein alpha subunits in rats. Neurosci Lett 1995;198:99-102
12. Romberg R, olofsen E, Sarton E, Teppema L, Dahan A: Pharmacodynamic effect of morphine-6-glucuronide versus morphine on hypoxic and hypercapnic breathing in healthy volunteers. ANESTHESIOIOGY 2003; 99:788-98
13. Grace D, Fee JP: A comparison of intrathecal morphine-6-glucuronide and intrathecal morphine sulfate as analgesics for total hip replacement. Anesth Analg 1996; 83:1055-9
14. Thompson PI, Bingham S, Andrews PL, Patel N, Joel SP, Slevin ML: Morphine 6-glucuronide: A metabolite of morphine with greater emetic potency than morphine in the ferret. Br J Pharmacol 1992; 106:3-8
15. Bickel U, SchumacherO, Kang YS, Voigt K: Poor permeability of morphine 3-glucuronide and morphine 6-glucuronide through the blood-brain barrier in the rat. J Pharmacol Exp Ther 1996; 278:107-13
16. Lötsch J, Skarke C, Schmidt H, Grösch S, Geisslinger G: The transfer half-life of morphine-6-beta-glucuronide from plasma to effect site assessed by pupil size measurement in healthy volunteers. A NESTHESIOIOGY 2001; 95:1329-38
17. Tegeder I, Meier S, Burian M, Schmidt H, Geisslinger G, L̈tsch J: Peripheral opioid analgesia in experimental human pain models. Brain 2003; 126:1092-102
18. Smith MT: Neuroexcitatory effects of morphine and hydromorphone: Evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol 2000; 27:524-8
19. Penson RT, Joel SP, Bakhshi K, Clark SJ, Langford RM, Slevin ML: Randomized placebo controlled trial of the activity of the morphine glucuronides. Clin Pharmacol Ther 2000; 68:667-76
20. Heger S, Maier C, otter K, Helwig U, Suttorp M: Morphine induced allodynia in a child with brain tumour. BMJ 1999; 319:627-9
21. Gardell LR, King T, Ossipov MH, Rice KC, Lai J, Vanderah TW, Porreca F: opioid receptor-mediated hyperalgesia and antinociceptive tolerance induced by sustained opiate delivery. Neurosci Lett 2006; 396:44-9
22. Raghavendra V, Tanga FY, DeLeo JA: Attenuation of morphine tolerance, withdrawal-induced hyperalgesia, and associated spinal inflammatory immune responses by propentofylline in rats. Neuropsychopharmacology 2004; 29:327-34
23. Sjogren P, Thunedborg LP, Christrup L, Hansen SH, Franks J: Is development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during long-term administration? Six case histories. Acta Anaesthesiol Scand 1998; 42:1070-5
24. Holtman JR Jr, Wala EP: Characterization of morphine-induced hyperalge- sia in male and female rats. Pain 2005; 114:62-70
25. Mao J, Sung B, Ji RR, Lim G: Chronic morphine induces downregulation of spinal glutamate transporters: Implications in morphine tolerance and abnormal pain sensitivity. J Neurosci 2002; 22:8312-23
26. Liang DY, Liao G, WangJ, UsukaJ, Guo Y, Peltz G, Clark JD: A genetic analysis of opioid-induced hyperalgesia in mice. ANESTHESIOIOGY 2006; 104: 1054-62
27. Tegeder I, Grosch S, Schmidtko A, Haussler A, Schmidt H, Niederberger E, Scholich K, Geisslinger G: G protein-independent G1 cell cycle block and apo- ptosis with morphine in adenocarcinoma cells: Involvement of p53 phosphory-lation. Cancer Res 2003; 63:1846-52